<DOC>
	<DOCNO>NCT02273349</DOCNO>
	<brief_summary>The objective study evaluate safety effectiveness RePneu Lung Volume Reduction Coil ( LVRC ) patient Alpha-1-Antitrypsin deficiency ( AATD ) cause emphysema . The hypothesis emphysema AATD patient show similar tissue destruction profile well symptoms thus respond favorably LVRC treatment , demonstrate improvement lung function , exercise capacity , quality life relative baseline status .</brief_summary>
	<brief_title>Lung Volume Reduction Coils Emphysema Alpha-1 Antitrypsin Deficiency</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Emphysema</mesh_term>
	<mesh_term>Pulmonary Emphysema</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Alpha 1-Antitrypsin Deficiency</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Alpha 1-Antitrypsin</mesh_term>
	<mesh_term>Protein C Inhibitor</mesh_term>
	<criteria>1 . Patient &gt; 18 year age , diagnose AATD emphysema 2 . CT scan indicate bilateral heterogeneous nonsevere homogeneous emphysema , sufficient lung parenchyma coil deployment , accordance manufacturer recommendation ( see section 5.2.4.1 ) . 3 . Patient post bronchodilator FEV1 le equal 45 % predict 4 . Total Lung Capacity &gt; 100 % 5 . Residual Volume ( RV ) &gt; 175 % predict 6 . Patient stop smoke minimum 8 week prior enter study 7 . Patient read , understood sign Informed Consent form 8 . Patient willing able attend require followup visit 9 . Patient willing able undergo bilateral LVRC treatment 10 . Patient receive Pneumococcal Influenza vaccination consistent local recommendation and/or policy 1 . Patient change FEV1 &gt; 20 % postbronchodilator . 2 . Patients DLCO &lt; 20 % predict 3 . Patient history recurrent clinically significant respiratory infection 4 . Patient uncontrolled pulmonary hypertension define right ventricular pressure &gt; 50mmHg evidenced echocardiogram 5 . Patient inability walk &gt; 140 meter ( 150 yard ) 6 minute 6 . Patient evidence disease may compromise survival lung cancer , renal failure , etc . 7 . Patient pregnant lactate 8 . Patient inability tolerate bronchoscopy moderate sedation anesthesia 9 . Patient clinically significant bronchiectasis 10 . Patient giant bullae &gt; 1/3 lung volume 11 . Patient previous LVR surgery , lung transplant lobectomy 12 . Patient involved pulmonary drug device study 30 day prior study 13 . Patient take &gt; 20mg prednisone ( similar steroid ) daily 14 . Patient antiplatelet agent ( Plavix ) anticoagulant therapy ( heparin coumadin ) wean prior procedure 15 . Patient condition would interfere completion study , follow assessment would adversely affect outcomes 16 . Patient severe homogeneous emphysema CT scan .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>